ABOUT US

Board of Directors

logo Vaxdyn blanco-verde

CURRICULUM


Juan José Infante

Dr. Infante obtained his Ph.D. (Microbiology and Biochemistry) from the University of Cádiz, Spain, and completed his academic training with a senior researcher position in the Department of Biochemistry of the University of Washington in Seattle, USA.

He joined the biotech private sector in 2007, serving as Chief Scientific Officer of Bionaturis and ADL Bionatur Solutions in Spain. Specialized in the development of biotechnological assets, covering intellectual property, R&D, and licensing, he became CEO of Vaxdyn in November 2013.

He brought the company into the CARB-X portfolio in 2019 and has since secured approximately €13 million in non-dilutive funding, including the EIC Accelerator grant, alongside the venture capital raised to take Vaxdyn’s vaccine technology to the threshold of clinical development.


Francisco Leon

Dr. León is a clinical and basic immunologist with a career spanning academia (NIH), biopharma (BMS, MedImmune/AstraZeneca, Janssen/Johnson & Johnson) and entrepreneurship, having served as CEO, CMO and CSO of several companies.

He has led or contributed to the development of six drugs that reached the market, most recently teplizumab (TZIELD®), approved to delay the onset of clinical type 1 diabetes, and has co-founded two biotech companies subsequently acquired by pharma: Celimmune, acquired by Amgen in 2017, and Provention Bio, acquired by Sanofi in 2023. He is currently Founder and CEO of Tolerance Bio.

An investor in Vaxdyn since 2017, he brings the Board experience in biotech governance and pharmaceutical development.


Dr. Ricardo Perdigão Henriques is the Managing Partner of Biovance Capital, a new €60M fund to invest in early-stage biotech companies across Europe. He is a Harvard and MIT-educated scientist turned investor with experience in scientific research, drug development, venture capital licensing, business development, and market analysis.

Ricardo has developed his career in the biomedical sector in both the USA and Portugal. Prior to Biovance Capital, he was the CEO of Bionova Capital, a venture capital firm that invested in health startups across Europe. At Bionova, he invested in the oncology startup CellmAbs, which was sold to BioNTech for potentially more than €1 billion, being the largest-ever biotech deal in Portugal.

He performed his PhD work at the Harvard Medical School in the field of microRNAs, and was a researcher at the Massachusetts Institute of Technology. Ricardo holds a B.Sc. in Biochemistry and a Ph.D. in Molecular Biology, both approved with the Highest Honors.


Cristina has more than 20 years of experience in finance and investment management and regularly lectures on these subjects at leading business schools, including IE Business School.

Since 2018, she has led the establishment, launch and investment activities of several Arcano vehicles under European Investment Bank mandates. These include Impacto Andalucía Innovación y Desarrollo, which finances R&D&I activities and projects. In recent years, she has overseen approximately €500 million in investments across a diversified range of asset classes.

Before joining Arcano, Cristina held structuring and analytical roles at international financial institutions.

Cristina holds dual bachelor’s degrees in Law and Business Administration from Carlos III University, a Master in Finance from IE Business School, a Master in Real Estate from Universidad Europea de Madrid and the CFA Certificate in ESG Investing.


CONTACT

Vaxdyn

Supported by

CONTACT US


Vaxdyn logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.